{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:24:38Z","timestamp":1767839078052,"version":"3.49.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,12]]},"DOI":"10.1097\/01.npr.0000445781.37062.16","type":"journal-article","created":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T20:59:51Z","timestamp":1396040391000},"page":"30-36","source":"Crossref","is-referenced-by-count":4,"title":["Herpes zoster"],"prefix":"10.1097","volume":"39","author":[{"given":"Denise D.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"9","key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jis214","article-title":"Varicella zoster virus transmission in the vaccine era: unmasking the role of herpes zoster.","volume":"205","author":"Bloch","year":"2012","journal-title":"J Infect Dis"},{"issue":"8","key":"R2-8-20210130","first-page":"2437","article-title":"Management of herpes zoster (shingles) and postherpetic neuralgia.","volume":"61","author":"Stankus","year":"2000","journal-title":"Am Fam Physician"},{"issue":"suppl 1","key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1002\/jmv.10364","article-title":"Varicella in Americans from NHANES III: implications for control through routine immunization.","volume":"70","author":"Kilgore","year":"2003","journal-title":"J Med Virol"},{"issue":"9","key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/infdis\/jis207","article-title":"Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings.","volume":"205","author":"Viner","year":"2012","journal-title":"J Infect Dis"},{"issue":"2","key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2165\/00002512-199710020-00002","article-title":"Herpes zoster and postherpetic neuralgia. Optimal treatment.","volume":"10","author":"Johnson","year":"1997","journal-title":"Drugs Aging"},{"issue":"1","key":"R7-8-20210130","first-page":"1","article-title":"Valacyclovir for the management of herpes viral infections.","volume":"10","author":"Chakrabarty","year":"2005","journal-title":"Skin Therapy Lett"},{"issue":"10","key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.mayocp.2012.05.021","article-title":"Chronic medical conditions as risk factors for herpes zoster.","volume":"87","author":"Joesoef","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0961203312470186","article-title":"Increased incidence of herpes zoster among patients with systemic lupus erythematosus.","volume":"22","author":"Chakravarty","year":"2013","journal-title":"Lupus"},{"issue":"1","key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3315\/jdcr.2013.1126","article-title":"The risk of herpes zoster in the anti-TNF- era: a case report and review of the literature.","volume":"7","author":"Di Costanzo","year":"2013","journal-title":"J Dermatol Case Rep"},{"issue":"6","key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/infdis\/jir425","article-title":"Persistence of varicella zoster virus DNA in saliva after herpes zoster.","volume":"204","author":"Nagel","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2340\/00015555-1284","article-title":"Beyond zoster: sensory and immune changes in zoster-affected dermatomes: a review.","volume":"92","author":"Ruocco","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"ITC31","DOI":"10.7326\/0003-4819-154-5-201103010-01003","article-title":"Herpes zoster.","volume":"154","author":"Wilson","year":"2011","journal-title":"Ann Intern Med"},{"issue":"9","key":"R14-8-20210130","first-page":"1723","article-title":"Evaluation and management of herpes zoster ophthalmicus.","volume":"66","author":"Shaikh","year":"2002","journal-title":"Am Fam Physician"},{"issue":"12","key":"R15-8-20210130","first-page":"1432","article-title":"Herpes zoster and postherpetic neuralgia: prevention and management.","volume":"83","author":"Fashner","year":"2011","journal-title":"Am Fam Physician"},{"issue":"2","key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.hrtlng.2010.05.059","article-title":"Facial herpes zoster complicated by varicella zoster virus (VZV) encephalitis: the diagnostic significance of atypical lymphocytes in cerebrospinal fluid (CSF).","volume":"40","author":"Cunha","year":"2011","journal-title":"Heart Lung"},{"issue":"suppl 2","key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1086\/522152","article-title":"The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.","volume":"197","author":"Schmader","year":"2008","journal-title":"J Infect Dis"},{"issue":"8","key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1532-5415.2007.01231.x","article-title":"Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster.","volume":"55","author":"Dworkin","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2146\/ajhp090118","article-title":"Herpes zoster and vaccination: a clinical review.","volume":"67","author":"Adams","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7326\/0003-4819-152-9-201005040-00005","article-title":"Barriers to the use of herpes zoster vaccine.","volume":"152","author":"Hurley","year":"2010","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"R23-8-20210130","first-page":"9","article-title":"Recommended immunization schedule for adults aged 19 years and olderUnited States 2013.","volume":"62","year":"2013","journal-title":"MMWR Surveill Summ"},{"issue":"8","key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cis1208","article-title":"Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications.","volume":"56","author":"Irwin","year":"2013","journal-title":"Clin Infect Dis"}],"container-title":["The Nurse Practitioner"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.NPR.0000445781.37062.16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T19:20:48Z","timestamp":1620933648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006205-201405000-00008"}},"subtitle":["A rash demanding careful evaluation"],"short-title":[],"issued":{"date-parts":[[2014,5,12]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/01.npr.0000445781.37062.16","relation":{},"ISSN":["0361-1817"],"issn-type":[{"value":"0361-1817","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,12]]}}}